A PHASE III, MULTICENTER, RANDOMISED, DOUBLEBLIND, PLACEBOCONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER
2022-06-28
عنوان الدراسة
A PHASE III, MULTICENTER, RANDOMISED, DOUBLEBLIND, PLACEBOCONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER
داعم الدراسة
Roche
دواء الدراسة
ATEZOLIZUMAB / PACLITAXEL
رقم بروتوكول الدراسة
MO39196
حالة الدراسة
Completed
موقع الدراسة
IMC (Closed), KFSH (Closed), KFMC (Closed)
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。